Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients

The investigators projected that BRCA1, BRCA2, and PALB2 gene testing in all breast cancer patients over one year could translate into 2,101 fewer breast or ovarian cancer cases, for example, and 633 related deaths, in the UK. In the US, the same analysis suggested that a year of unselected testing could prevent more than 9,700 cancer cases and 2,406 breast or ovarian cancer deaths.

The analyses took into account the potential interventions, enhanced screening, and cascade testing options available for those with risky germline variants and their family members, the team explained, including mammography, magnetic resonance imaging, chemoprevention treatments, or double mastectomy/oophorectomy surgeries.

Source: https://www.genomeweb.com/molecular-diagnostics/study-finds-breast-ovarian-cancer-gene-tests-cost-effective-unselected-breast